Dual-fluorophore quantitative high-throughput screen for inhibitors of BRCT-phosphoprotein interaction.
暂无分享,去创建一个
Sam Michael | Christopher P Austin | Anton Simeonov | James Inglese | Ajit Jadhav | Adam Yasgar | Carleen Klumpp | Adam Yasgar | A. Jadhav | C. Austin | A. Simeonov | James Inglese | A. Natarajan | Sam Michael | Amarnath Natarajan | G L Lokesh | G. L. Lokesh | C. Klumpp
[1] Michelle R. Arkin,et al. Binding of small molecules to an adaptive protein–protein interface , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[2] Anton Simeonov,et al. Quantitative High-Throughput Screen Identifies Inhibitors of the Schistosoma mansoni Redox Cascade , 2008, PLoS neglected tropical diseases.
[3] Junjie Chen,et al. CCDC98 is a BRCA1-BRCT domain–binding protein involved in the DNA damage response , 2007, Nature Structural &Molecular Biology.
[4] P. Cleveland,et al. Nanoliter dispensing for uHTS using pin tools. , 2005, Assay and drug development technologies.
[5] Hua Tang,et al. Studies on Repository Compound Stability in DMSO under Various Conditions , 2003, Journal of biomolecular screening.
[6] Sam Michael,et al. Compound Management for Quantitative High-Throughput Screening , 2008, JALA.
[7] Junjie Chen,et al. DNA Damage-Induced Cell Cycle Checkpoint Control Requires CtIP, a Phosphorylation-Dependent Binding Partner of BRCA1 C-Terminal Domains , 2004, Molecular and Cellular Biology.
[8] J. Tesmer. Pharmacology. Hitting the hot spots of cell signaling cascades. , 2006, Science.
[9] Xiaochun Yu,et al. CCDC98 targets BRCA1 to DNA damage sites , 2007, Nature Structural &Molecular Biology.
[10] David Eisenberg,et al. A Novel Inhibitor of Mycobacterium tuberculosis Pantothenate Synthetase , 2007, Journal of biomolecular screening.
[11] B. Shoichet,et al. High-throughput assays for promiscuous inhibitors , 2005, Nature chemical biology.
[12] Junjie Chen,et al. Ubiquitin-Binding Protein RAP80 Mediates BRCA1-Dependent DNA Damage Response , 2007, Science.
[13] Yigong Shi,et al. Structure of the BRCT repeats of BRCA1 bound to a BACH1 phosphopeptide: implications for signaling. , 2004, Molecular cell.
[14] Drew M. Lowery,et al. Structure and mechanism of BRCA1 BRCT domain recognition of phosphorylated BACH1 with implications for cancer , 2004, Nature Structural &Molecular Biology.
[15] B. K. Muralidhara,et al. Thermodynamics of phosphopeptide tethering to BRCT: the structural minima for inhibitor design. , 2007, Journal of the American Chemical Society.
[16] T Pérez-Ruiz,et al. Simultaneous determination of doxorubicin, daunorubicin, and idarubicin by capillary electrophoresis with laser‐induced fluorescence detection , 2001, Electrophoresis.
[17] D. Sgroi,et al. BACH1, a Novel Helicase-like Protein, Interacts Directly with BRCA1 and Contributes to Its DNA Repair Function , 2001, Cell.
[18] A. Bogan,et al. Anatomy of hot spots in protein interfaces. , 1998, Journal of molecular biology.
[19] S. Macura,et al. Structural basis of BACH1 phosphopeptide recognition by BRCA1 tandem BRCT domains. , 2004, Structure.
[20] Christopher P Austin,et al. A high-throughput screen for aggregation-based inhibition in a large compound library. , 2007, Journal of medicinal chemistry.
[21] A. Varma,et al. Structural basis for cell cycle checkpoint control by the BRCA1-CtIP complex. , 2005, Biochemistry.
[22] Michael B Yaffe,et al. BRCT Repeats As Phosphopeptide-Binding Modules Involved in Protein Targeting , 2003, Science.
[23] Adam Yasgar,et al. Quantitative high-throughput screening: a titration-based approach that efficiently identifies biological activities in large chemical libraries. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[24] Kim E. Garbison,et al. The Minimum Significant Ratio: A Statistical Parameter to Characterize the Reproducibility of Potency Estimates from Concentration-Response Assays and Estimation by Replicate-Experiment Studies , 2006, Journal of biomolecular screening.
[25] J. Glover,et al. Structural basis of phosphopeptide recognition by the BRCT domain of BRCA1 , 2004, Nature Structural &Molecular Biology.
[26] A. Hill,et al. The possible effects of the aggregation of the molecules of haemoglobin on its dissociation curves , 1910 .
[27] Steven P Gygi,et al. Abraxas and RAP80 Form a BRCA1 Protein Complex Required for the DNA Damage Response , 2007, Science.
[28] Michelle R. Arkin,et al. Small-molecule inhibitors of protein–protein interactions: progressing towards the dream , 2004, Nature Reviews Drug Discovery.
[29] Georges Mer,et al. The BRCT Domain Is a Phospho-Protein Binding Domain , 2003, Science.
[30] Aedín C Culhane,et al. RAP80 Targets BRCA1 to Specific Ubiquitin Structures at DNA Damage Sites , 2007, Science.
[31] Sandra L. Nelson,et al. The Effect of Room-Temperature Storage on the Stability of Compounds in DMSO , 2003, Journal of biomolecular screening.
[32] Peter J. Coassin,et al. Piezo- and solenoid valve-based liquid dispensing for miniaturized assays. , 2005, Assay and drug development technologies.
[33] Christopher P Austin,et al. High-throughput screening assays for the identification of chemical probes. , 2007, Nature chemical biology.
[34] Thomas D. Y. Chung,et al. A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays , 1999, Journal of biomolecular screening.
[35] A. Natarajan,et al. High-throughput fluorescence polarization assay to identify small molecule inhibitors of BRCT domains of breast cancer gene 1. , 2006, Analytical biochemistry.
[36] A. Bowcock,et al. The C-terminal (BRCT) Domains of BRCA1 Interact in Vivo with CtIP, a Protein Implicated in the CtBP Pathway of Transcriptional Repression* , 1998, The Journal of Biological Chemistry.
[37] Junjie Chen,et al. Phosphopeptide Binding Specificities of BRCA1 COOH-terminal (BRCT) Domains* , 2003, Journal of Biological Chemistry.
[38] T. Insel,et al. NIH Molecular Libraries Initiative , 2004, Science.